Repligen | RGEN - Ebitda


Repligen reported $43.77M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Agilent USD 456M 84M Dec/2025
Align Technology USD 229.14M 31.74M Mar/2026
Bio Techne USD 116.71M 13.29M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Bruker USD 143.2M 33.2M Jun/2026
Charles River Laboratories USD 229.8M 28.26M Mar/2026
Danaher USD 1.84B 81M Jun/2026
Dentsply International USD 129M 6M Mar/2026
General Electric Aerospace USD 3.06B 219M Jun/2026
Henry Schein USD 288M 1000K Jun/2026
Illumina USD 330M 80M Jun/2026
IQVIA Holdings USD 994M 62M Jun/2026
Mettler Toledo International USD 322.64M 43.66M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Pfizer USD 6.01B 18M Jun/2026
Repligen USD 43.77M 3.76M Jun/2026
Revvity USD 228.18M 44.73M Jun/2026
Standard Biotools USD -8.01M 7.8M Mar/2026
Thermo Fisher Scientific USD 3.55B 845M Jun/2026
Waters USD 712M 545M Jun/2026
West Pharmaceutical Services USD 243.6M 17.4M Jun/2026